Guidance warns against using 2 phthalates as drug excipient

03/27/2012 | InPharm.com

The FDA said in draft guidance that drugmakers should avoid using dibutyl phthalate and di(2-ethylhexyl) phthalate as an excipient in pharmaceutical and biologic products because they could be toxic to humans. The agency's Inactive Ingredients Database lists possible alternatives to the two phthalates.

View Full Article in:

InPharm.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX